Transplacental passage and breast milk concentrations of hydralazine |
| |
Authors: | H. Liedholm E. Wåhlin-Boll A. Hanson I. Ingemarsson A. Melander |
| |
Affiliation: | (1) Departments of Medicine, Obstetrics and Gynaecology, Lund University Hospital, Sweden;(2) Departments of Clinical Chemistry, Section of Toxicology, and Clinical Pharmacology, Malmö General Hospital, University of Lund, Lund and Malmö, Sweden |
| |
Abstract: | Summary The concentrations of real and apparent (= real hydralazine + acid-labile hydrazones) hydralazine in maternal and umbilical plasma obtained at delivery of 6 women treated with hydralazine and atenolol for pregnancy hypertension were measured by gas chromatography. In one of the patients, the concentrations of the same substances were subsequently measured in breast milk. Apparent hydralazine reached higher levels in umbilical than in maternal blood. The concentration of real hydralazine seemed to be at least as high in the fetus as in the mother. On the other hand, even though the fraction of real (i.e. presumably active) hydralazine was greater in milk than in plasma, the total concentration was smaller, and the estimated dose per milk feed of 75ml would not exceed 0.013mg. Thus, hydralazine treatment of the pregnant woman would expose her fetus to effective concentrations of the drug, but breast feeding would not result in a clinically relevant concentration in the infant. |
| |
Keywords: | hydralazine pregnancy hypertension maternal blood level neonatal blood level transplacental passage breast milk level |
本文献已被 SpringerLink 等数据库收录! |
|